– USA, CA – Saama Technologies, Inc. today announced the appointments of six new members to its Board of Directors:
- Suresh Katta, Founder and CEO of Saama
- Ian Read, former CEO and Executive Chairman of Pfizer
- Clive Meanwell, Founder and former CEO of The Medicines Company
- Steve Wise, Head of Global Healthcare, Carlyle
- Joe Bress, Managing Director, Carlyle
- Ashley Evans, Managing Director, Carlyle
- Andrea Jackson, Director, Northpond Ventures
“With our landmark strategic investment fully closed, Saama is doubling down on its efforts to empower all pharmaceutical and biotechnology companies to redefine and accelerate their drug development paradigms and regulatory submission processes through the democratized use of AI-driven analytics solutions and platforms. Saama and the entire life sciences industry is poised for growth in this exciting new era of clinical development, and the addition of Ian and Clive to our Board will enable us to have an even greater impact than ever before,” said Suresh Katta.
This announcement follows the recent strategic investment of up to $430M by Carlyle and co-investors, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners.
About Ian Read
Ian Read joined Pfizer in 1978. Prior to his tenure as CEO, Ian served as Senior Vice President and Group President of Pfizer’s Worldwide Biopharmaceutical Businesses, overseeing five global business units: Primary Care, Specialty Care, Oncology, Established Products, and Emerging Markets. He also held positions in several of the company’s largest, fastest-growing operations, including CFO, Pfizer Mexico, and Country Manager, Pfizer Brazil.
“I am looking forward to the opportunity to help Saama architect and advance the future of clinical development and the life sciences industry. It’s an honor to join Saama’s Board of Directors and the industry experts who comprise it,” said Ian Read.
About Clive Meanwell
Clive Meanwell is Executive Chairman of Population Health Partners LLC, a global investment firm, and CEO of Population Health Investment Corporation, a special purpose acquisition company. In 1996, Dr. Meanwell founded biopharmaceutical company The Medicines Company. He served as a member of the Board of Directors and held a range of leadership positions including Chairman, Executive Chairman, CEO, and CIO until January 6, 2020, when Novartis AG acquired the company.
“It’s exciting to join Saama’s team in their mission of empowering pharmaceutical and biotechnology companies to bring better medical treatments to market faster, more efficiently, and with ever-greater validity,” said Clive Meanwell.
About Saama Technologies, Inc.
Saama is the #1 AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Today, over 50 biotech companies use Saama’s award-winning Life Science Analytics Cloud platform on more than 1,500 studies, including many of the top 20 pharmaceutical companies. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications more efficiently and bring drugs to market faster.
For more information : https://www.saama.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
